ADAR1 levels in rectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a protein called ADAR1 in rectal cancer tissue. It aims to see how ADAR1 levels might be related to the cancer and help doctors understand the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early or locally advanced rectal cancer (cancer that has not spread to other parts of the body).
- You are generally well enough to get around and care for yourself (ECOG score 0-2).
- You do not have any medical reasons that would prevent you from having chemotherapy or radiation therapy.
- You have not been told that your cancer has spread to distant parts of the body (metastatic).
- You do not have another type of cancer (second primary cancer).
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving an extra, targeted radiation dose (adaptive radiation boost) after standard treatment can improve outcomes for people with rectal cancer. You may be eligible if you have stage T2-3 N0-1 rectal cancer and can undergo MRI scans and certain chemotherapies.
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
This study looks at how well rectal cancer responds to chemotherapy and radiation before surgery. It uses a genetic test on tumor tissue to predict whether the treatment will work for you.
This study looks at how well cancer found on scans matches the actual cancer seen under the microscope after surgery. It may help improve how doctors plan treatment for colon, sigmoid, or rectal adenocarcinoma.
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
This trial tests whether an MRI scan done during chemoradiation can help doctors track how rectal cancer treatment is working. It may improve how they measure response early so treatment planning can be better tailored.
Hear when a new Rectum Cancer, Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.